References
- Alakus H, Monig SP, Warnecke-Eberz U, et al (2009). Association of the GNAS1 T393C polymorphism with tumor stage and survival in gastric cancer. World J Gastroenterol, 15, 6061-7. https://doi.org/10.3748/wjg.15.6061
- Bond GL, Hu W, Bond EE, et al (2004). A single nucleotide polymorphism in the Mdm2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell, 119, 591-602. https://doi.org/10.1016/j.cell.2004.11.022
- Brosh R, Rotter V (2009). When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer, 9, 701-13. https://doi.org/10.1038/nrc2693
- DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88. https://doi.org/10.1016/0197-2456(86)90046-2
- Egger M, Davey Smith G, Schneider M, Minder C (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ, 315, 629-34. https://doi.org/10.1136/bmj.315.7109.629
- Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90. https://doi.org/10.3322/caac.20107
- Levine AJ, Oren M (2009). The first 30 years of p53: growing ever more complex. Nat Rev Cancer, 9, 749-58. https://doi.org/10.1038/nrc2723
- Li X, Yang XX, Hu NY, et al (2011). A risk-associated single nucleotide polymorphism of SMAD7 is common to colorectal, gastric, and lung cancers in a Han Chinese population. Mol Biol Rep, 38, 5093-7. https://doi.org/10.1007/s11033-010-0656-3
- Ma Y, Bian J, Cao H (2013). Mdm2 SNP309 rs2279744 polymorphism and gastric cancer risk: a meta-analysis. PLoS One, 8, e56918. https://doi.org/10.1371/journal.pone.0056918
- Mantel N, Haenszel W (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst, 22, 719-48.
- Ohmiya N, Taguchi A, Mabuchi N, et al (2006). Mdm2 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis. J Clin Oncol, 24, 4434-40. https://doi.org/10.1200/JCO.2005.04.1459
- Pan X, Li Y, Feng J, et al (2013). A functional polymorphism T309G in Mdm2 gene promoter, intensified by Helicobacter pylori lipopolysaccharide, is associated with both an increased susceptibility and poor prognosis of gastric carcinoma in Chinese patients. BMC Cancer, 13, 126. https://doi.org/10.1186/1471-2407-13-126
- Saeki N, Ono H, Sakamoto H, Yoshida T (2013). Genetic factors related to gastric cancer susceptibility identified using a genome-wide association study. Cancer Sci, 104, 1-8. https://doi.org/10.1111/cas.12042
- Shibata T, Arisawa T, Tahara T, et al (2009). Selenoprotein S (SEPS1) gene -105G>A promoter polymorphism influences the susceptibility to gastric cancer in the Japanese population. BMC Gastroenterol, 9, 2. https://doi.org/10.1186/1471-230X-9-2
- Xu M, Tao G, Kang M, et al (2013). A polymorphism (rs2295080) in mTOR promoter region and its association with gastric cancer in a Chinese population. PLoS One, 8, e60080. https://doi.org/10.1371/journal.pone.0060080
- Yang M, Guo Y, Zhang X, et al (2007). Interaction of P53 Arg72Pro and Mdm2 T309G polymorphisms and their associations with risk of gastric cardia cancer. Carcinogenesis, 28, 1996-2001. https://doi.org/10.1093/carcin/bgm168
- Yang Z, Shu X, Chen L, et al (2012). Expression of p53-Mdm2 feedback loop related proteins in different gastric pathologies in relation to Helicobacter pylori infection: implications in gastric carcinogenesis. Clin Res Hepatol Gastroenterol, 36, 235-43. https://doi.org/10.1016/j.clinre.2011.11.009
- Zhang Q, Ma YY, Wang HJ, et al (2013). Meta-analysis of the association between P53 codon 72 polymorphisms and gastric cancer. J Surg Oncol, 107, 360-6. https://doi.org/10.1002/jso.23233
- Zhao P, Dai M, Chen W, Li N (2010). Cancer trends in China. Jpn J Clin Oncol, 40, 281-5. https://doi.org/10.1093/jjco/hyp187
- Zou TH, Wang ZH, Fang JY (2013). Positive association between Toll-like receptor 4 gene +896A/G polymorphism and susceptibility to gastric carcinogenesis: a meta-analysis. Tumour Biol, 34, 2441-50. https://doi.org/10.1007/s13277-013-0795-y
Cited by
- Pemetrexed is Mildly Active with Good Tolerability in Treating Patients with Gastric Cancer vol.15, pp.17, 2014, https://doi.org/10.7314/APJCP.2014.15.17.7137
- Effects of p53 Codon 72 and MDM2 SNP309 Polymorphisms on Gastric Cancer Risk among the Iranian Population vol.15, pp.17, 2014, https://doi.org/10.7314/APJCP.2014.15.17.7413
- Goseki Grade and Tumour Location Influence Survival of Patients with Gastric Cancer vol.15, pp.3, 2014, https://doi.org/10.7314/APJCP.2014.15.3.1429
- Lack of Association of the MDR1 C3435T Polymorphism with Susceptibility to Gastric Cancer and Peptic Ulcer: a Systemic Review and Meta-analysis vol.15, pp.7, 2014, https://doi.org/10.7314/APJCP.2014.15.7.3021
- Genetic association of single nucleotide polymorphisms in P53 pathway with gastric cancer risk in a Chinese Han population vol.32, pp.1, 2015, https://doi.org/10.1007/s12032-014-0401-1